Rezolute (NASDAQ:RZLT) Stock Price Crosses Below 200-Day Moving Average - What's Next?

Key Points

• Rezolute shares fell below the 200-day moving average of $3.84, reaching $3.73 before last trading at $3.82 on volume of 1.54 million shares. The stock’s 50-day moving average is higher at $4.32.
• Analyst sentiment remains mixed but leans positive: 12 analysts rate the stock a Buy and two rate it a Sell, resulting in a “Moderate Buy” consensus and an average price target of $11.22.
• Rezolute missed quarterly earnings expectations, reporting a loss of $0.20 per share versus the anticipated $0.15 loss. The clinical-stage biotech is developing RZ358, an investigational treatment for congenital hyperinsulinism.

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $3.84 and traded as low as $3.73. Rezolute shares last traded at $3.82, with a volume of 1,543,500 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on RZLT shares. Weiss Ratings restated a "sell (d-)" rating on shares of Rezolute in a research report on Thursday, October 15th. HC Wainwright boosted their target price on Rezolute from $5.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, September 25th. Zacks Research lowered Rezolute from a "hold" rating to a "strong sell" rating in a research note on Tuesday, October 13th. Lake Street Capital boosted their target price on shares of Rezolute from $9.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, October 6th. Finally, Craig Hallum upgraded shares of Rezolute from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $4.00 to $7.00 in a research report on Tuesday, September 29th. Twelve research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $11.22.

Rezolute Stock Performance

The company has a market cap of $369.51 million, a P/E ratio of -5.03 and a beta of 0.53. The company has a fifty day moving average price of $4.32 and a two-hundred day moving average price of $3.84.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings results on Thursday, September 24th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). Research analysts anticipate that Rezolute, Inc. will post -0.63 EPS for the current year.

Institutional Trading of Rezolute

Hedge funds and other institutional investors have recently modified their holdings of the stock. Auxano Advisors LLC acquired a new position in Rezolute in the 2nd quarter valued at $52,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Rezolute during the 2nd quarter worth $75,000. WINTON GROUP Ltd bought a new stake in Rezolute during the second quarter worth about $88,000. Integrated Wealth Concepts LLC bought a new position in Rezolute in the 2nd quarter valued at about $143,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Rezolute during the first quarter valued at approximately $90,000. Institutional investors own 82.97% of the company's stock.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company's lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.